Actuate Therapeutics, Inc. SEC filings ACTU
Actuate Therapeutics, Inc. has 192 filings in SEC EDGAR's recent list, going back to Oct 8, 2015. Its latest annual report, Form ARS, was filed on Apr 9, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (listing notice). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Oct 26, 2026 | — |
| DRS | Filing | Jun 8, 2026 | — |
| EFFECT | Filing | Sep 8, 2025 | — |
| CORRESP | Letter to the SEC | Sep 4, 2025 | — |
| CORRESP | Letter to the SEC | Sep 2, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 26, 2025 | — |
| DRS | Filing | Aug 18, 2025 | — |
| EFFECT | Filing | Aug 4, 2025 | — |
| CORRESP | Letter to the SEC | Jul 31, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 31, 2025 | — |
| D | Filing | Jul 7, 2025 | — |
| EFFECT | Filing | Apr 16, 2025 | — |
| CORRESP | Letter to the SEC | Apr 14, 2025 | — |
| D | Filing | Apr 10, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 1, 2025 | — |
| SEC STAFF LETTER | Filing | Aug 13, 2024 | — |
| POS EX | Filing | Aug 13, 2024 | — |
| EFFECT | Filing | Aug 12, 2024 | — |
| CERT | Filing | Aug 12, 2024 | — |
| CORRESP | Letter to the SEC | Aug 12, 2024 | — |
| CORRESP | Letter to the SEC | Aug 12, 2024 | — |
| 8-A12B/A | Form 8-a12b/a | Aug 12, 2024 | — |
| CORRESP | Letter to the SEC | Aug 2, 2024 | — |
| CORRESP | Letter to the SEC | Aug 2, 2024 | — |
| CORRESP | Letter to the SEC | Jul 30, 2024 | — |
| CORRESP | Letter to the SEC | Jul 30, 2024 | — |
| CORRESP | Letter to the SEC | Jul 26, 2024 | — |
| CORRESP | Letter to the SEC | Jul 26, 2024 | — |
| CORRESP | Letter to the SEC | Jul 19, 2024 | — |
| CORRESP | Letter to the SEC | Jul 19, 2024 | — |
| CORRESP | Letter to the SEC | Jul 17, 2024 | — |
| CORRESP | Letter to the SEC | Jul 17, 2024 | — |
| CORRESP | Letter to the SEC | Jul 15, 2024 | — |
| CORRESP | Letter to the SEC | Jul 15, 2024 | — |
| CORRESP | Letter to the SEC | Jun 21, 2024 | — |
| 8-A12B | Filing | Jun 20, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 18, 2024 | — |
| CORRESP | Letter to the SEC | Jun 11, 2024 | — |
| UPLOAD | Letter from the SEC | May 31, 2024 | — |
| CORRESP | Letter to the SEC | May 24, 2024 | — |
| UPLOAD | Letter from the SEC | May 20, 2024 | — |
| DRS/A | Filing | May 13, 2024 | — |
| DRSLTR | Filing | May 10, 2024 | — |
| UPLOAD | Letter from the SEC | May 8, 2024 | — |
| DRSLTR | Filing | Apr 30, 2024 | — |
| DRS/A | Filing | Apr 30, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 19, 2024 | — |
| DRSLTR | Filing | Apr 9, 2024 | — |
| DRS/A | Filing | Apr 9, 2024 | — |
| SEC STAFF LETTER | Filing | Apr 3, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 1, 2024 | — |
| D | Filing | Mar 6, 2024 | — |
| DRSLTR | Filing | Mar 4, 2024 | — |
| DRS | Filing | Mar 4, 2024 | — |
| D/A | Filing | Dec 15, 2022 | — |
| D | Filing | Oct 19, 2022 | — |
| D | Filing | Dec 10, 2020 | — |
| D/A | Filing | Nov 14, 2019 | — |
| D | Filing | Oct 15, 2019 | — |
| D | Filing | May 13, 2019 | — |
| D | Filing | Sep 12, 2018 | — |
| D | Filing | Mar 20, 2017 | — |
| D | Filing | Feb 3, 2017 | — |
| D | Filing | Oct 8, 2015 | — |
Showing 64 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ACTU (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Fort Worth, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1652935
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.